DK1267869T3 - Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed - Google Patents

Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed

Info

Publication number
DK1267869T3
DK1267869T3 DK01910051T DK01910051T DK1267869T3 DK 1267869 T3 DK1267869 T3 DK 1267869T3 DK 01910051 T DK01910051 T DK 01910051T DK 01910051 T DK01910051 T DK 01910051T DK 1267869 T3 DK1267869 T3 DK 1267869T3
Authority
DK
Denmark
Prior art keywords
dependence
tolerance
treatment
glutamate receptor
metabotropic glutamate
Prior art date
Application number
DK01910051T
Other languages
Danish (da)
English (en)
Inventor
Mauro Corsi
Francois Conquet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9887294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1267869(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1267869T3 publication Critical patent/DK1267869T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fertilizers (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
DK01910051T 2000-03-09 2001-03-09 Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed DK1267869T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0005700.0A GB0005700D0 (en) 2000-03-09 2000-03-09 Therapy

Publications (1)

Publication Number Publication Date
DK1267869T3 true DK1267869T3 (da) 2004-09-20

Family

ID=9887294

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01910051T DK1267869T3 (da) 2000-03-09 2001-03-09 Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed

Country Status (16)

Country Link
US (1) US20030195139A1 (https=)
EP (1) EP1267869B1 (https=)
JP (1) JP2003525902A (https=)
CN (1) CN1427720A (https=)
AT (1) ATE267013T1 (https=)
AU (1) AU783869B2 (https=)
CA (1) CA2402341A1 (https=)
DE (1) DE60103384T2 (https=)
DK (1) DK1267869T3 (https=)
ES (1) ES2220727T3 (https=)
GB (1) GB0005700D0 (https=)
NZ (1) NZ521228A (https=)
PT (1) PT1267869E (https=)
SE (1) SE1267869T5 (https=)
TR (1) TR200401862T4 (https=)
WO (1) WO2001066113A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314192A (pt) 2002-09-10 2005-07-26 Novartis Ag Antagonistas de receptores de mglu para tratamento de distúrbios associados com receptores de mglu incluindo vìcio e depressão
US8778979B2 (en) 2005-04-05 2014-07-15 Yale University Glutamate agents in the treatment of mental disorders
US20060264381A1 (en) * 2005-05-05 2006-11-23 Bear Mark F Methods of treating obsessive compulsive disorder
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7531541B2 (en) * 2005-09-20 2009-05-12 Vanderbilt University Partial mGluR5 antagonists for treatment of anxiety and CNS disorders
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
US20130123254A1 (en) * 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
CA3066711A1 (en) * 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
CA3067688A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
MX2023000664A (es) * 2020-07-17 2023-02-27 Novartis Ag Uso de antagonistas de mglur5.
AU2021404023A1 (en) * 2020-12-14 2023-06-29 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5543698A (en) * 1994-09-27 1996-08-06 Allen-Bradley Company, Inc. Method and apparatus used with AC motor for detecting unbalance
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
CA2287591A1 (en) * 1997-03-14 1998-09-17 The Johns Hopkins University School Of Medicine Synaptic activation protein compositions and method
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
EP1117403B1 (en) * 1998-10-02 2003-12-10 Novartis AG Mglur5 antagonists for the treatment of pain and anxiety
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
EP1183238A1 (en) * 1999-05-17 2002-03-06 Eli Lilly And Company Metabotropic glutamate receptor antagonists
US6666209B2 (en) * 2001-02-20 2003-12-23 3M Innovative Properties Company Method and system of calibrating air flow in a respirator system

Also Published As

Publication number Publication date
DE60103384D1 (de) 2004-06-24
AU3763401A (en) 2001-09-17
SE1267869T5 (https=) 2004-09-07
EP1267869B1 (en) 2004-05-19
WO2001066113A1 (en) 2001-09-13
CN1427720A (zh) 2003-07-02
NZ521228A (en) 2004-04-30
EP1267869A1 (en) 2003-01-02
AU783869B2 (en) 2005-12-15
ES2220727T3 (es) 2004-12-16
HK1053262A1 (en) 2003-10-17
SE1267869T3 (https=) 2004-08-31
ATE267013T1 (de) 2004-06-15
TR200401862T4 (tr) 2004-10-21
CA2402341A1 (en) 2001-09-13
DE60103384T2 (de) 2005-06-16
GB0005700D0 (en) 2000-05-03
JP2003525902A (ja) 2003-09-02
US20030195139A1 (en) 2003-10-16
PT1267869E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
DK1267869T3 (da) Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed
DK0901374T3 (da) Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
ATE300299T1 (de) Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
ATE420644T1 (de) Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
ATE328874T1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
DE60205776D1 (en) Indolinon-derivative als protein-kinasehemmer
DK1446387T3 (da) Substituerede aryl, 1,4-pyrazinderivater
YU50001A (sh) 4-(heterociklilsulfonamido)-5-metoksi-6-(2-metoksi-fenoksi) -2-fenil-ili piridil-pirimidini kao antagonisti endotelinskih receptora
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
DE69732868D1 (de) Mittel gegen Juckreiz
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
DE59914814D1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
DK1392643T3 (da) (1S)-1,2,3,4-tetrahydro-1-naphthalenylbenzamider, der er trisubstituerede ved N, og som inhiberer receptorer indeholdende P2X3 og P2X2/3
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
DE60015599D1 (de) 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
DE60214676D1 (de) Hochaffine antagonisten der elr-cxc chemokine
ATE449078T1 (de) 5-ht7 rezeptor-antagonisten
SE0302361D0 (sv) Inhibering av upptagning av monoamin
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
PT950056E (pt) N-(piridinilamino) isoindolinas e compostos relacionados